Provectus shareholders approve reverse stock split, elect directors at annual meeting

PROVECTUS BIOPHARMACEUTICALS, INC.

All five director nominees elected: Bailey, Horowitz, Lacey, Pershing, Rodrigues; 102.4M broker non-votes.
Advisory say-on-pay approved with 206.7M for vs 9.6M against.
Ratification of Marcum LLP as auditor for 2022 passed with 313.4M for.
Authorization to implement reverse stock split (1:10 to 1:50) approved with 300.5M for.
Authorization to reduce authorized shares proportionally to reverse split ratio approved with 302.5M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.